Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Baxter International revenue
Baxter International's revenue is $10.6 billion.
What is Baxter International's revenue?
- Baxter International's revenue growth from 2002 to 2024 is 31.32%.
- Baxter International has 48,000 employees, and the revenue per employee ratio is $221,583.
- Baxter International's peak quarterly revenue was $4.2B in 2014(q2).
- Baxter International peak revenue was $13.9B in 2012.
- Baxter International annual revenue for 2023 was 10.4B, 3.01% growth from 2022.
- Baxter International annual revenue for 2024 was 10.6B, 2.66% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Baxter International historical revenue
Baxter International's peak revenue was $13.9B in 2012. The peak quarterly revenue was $4.2B in 2014(q2).
Baxter International's revenue increased from $8.1b in 2002 to $10.6B currently. That's a 31.32% change in annual revenue.
Baxter International annual revenue
Baxter International annual revenue over time
| Fiscal year / year | Baxter International revenue |
|---|---|
| 2009 | $12.6B |
| 2010 | $12.8B |
| 2011 | $13.9B |
| 2012 | $13.9B |
| 2013 | $9.4B |
| 2014 | $10.7B |
| 2015 | $10.0B |
| 2016 | $10.2B |
| 2017 | $10.6B |
| 2018 | $11.1B |
| 2019 | $11.4B |
| 2020 | $11.7B |
| 2021 | $12.1B |
| 2022 | $10.1B |
| 2023 | $10.4B |
| 2024 | $10.6B |
How accurately did Baxter International's revenue projections match actual performance?
Baxter International annual growth
Baxter International saw the greatest revenue growth in 2022, when revenue increased by 18.22%.
Baxter International had the lowest revenue growth in 2013, when revenue changed by -32.46%.
Baxter International annual growth rate over time
| Year | Baxter International growth |
|---|---|
| 2009 | 2%↑ |
| 2010 | 2%↑ |
| 2011 | 8%↑ |
| 2012 | 0%↑ |
| 2013 | -32%↓ |
| 2014 | 14%↑ |
| 2015 | -7%↓ |
| 2016 | 2%↑ |
| 2017 | 4%↑ |
| 2018 | 5%↑ |
| 2019 | 2%↑ |
| 2020 | 3%↑ |
| 2021 | 4%↑ |
| 2022 | -17%↓ |
| 2023 | 3%↑ |
| 2024 | 3%↑ |
Baxter International quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Baxter International quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | - | - | $3.1B | $3.5B |
| 2010 | $2.9B | $3.2B | $3.2B | $3.5B |
| 2011 | $3.3B | $3.5B | $3.5B | $3.6B |
| 2012 | $3.4B | $3.6B | $3.5B | $3.5B |
| 2013 | $3.4B | $3.7B | $3.7B | ($1.2B) |
| 2014 | $3.8B | $4.2B | $2.7B | $2.8B |
| 2015 | $2.4B | $2.5B | $2.5B | $2.6B |
| 2016 | $2.4B | $2.6B | $2.6B | $2.6B |
| 2017 | $2.5B | $2.6B | $2.7B | $2.8B |
| 2018 | $2.7B | $2.8B | $2.8B | $2.8B |
| 2019 | $2.6B | $2.8B | $2.9B | $3.0B |
| 2020 | $2.8B | $2.7B | $3.0B | $3.2B |
| 2021 | $2.9B | $3.1B | $3.2B | $2.9B |
| 2022 | $3.7B | $3.6B | $3.6B | ($704.0M) |
| 2023 | $3.5B | $3.7B | $2.6B | $2.7B |
| 2024 | $3.6B | $3.8B | $2.7B | $2.8B |
Baxter International jobs nearby
Do you work at Baxter International?
Is Baxter International transparent about its revenue structure?
Baxter International financial information
| CEO | Jose E. Almeida |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 48,000 |
| Date Founded | 1931 |
| Headquarters | Deerfield, Illinois |
| Number of Locations | 9 |
| Revenue | $10.6B |
| Net Income | -$2,433,000,000 |
| Gross Proft | $4.0B (2024) |
| PE Ratio | -71.41 |
| Tax Rate | -0.1% |
| Market Capitalization | $46.3B |
| Total Assets | $28,287,000,000 |
| Ticker | BAX |
Baxter International jobs you might like
Baxter International financing
Baxter International received early financing of $1.7B on 2019-05-15.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $1.7B | 05/2019 |
| Grant | $1.6M | 04/2021 |
Baxter International investors
| Investors | Security type |
|---|---|
| Federal Ministry of Education and Research Germany | Grant |
Baxter International competitors
Baxter International's top competitor, Cardinal Health, earned an annual revenue of $226.8B.
Baxter International's smallest competitor is Seagen with revenue of $2.0B last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Stryker | $69,470 | $22.6B | 43,000 | 2,118 |
| Amgen | $93,349 | $33.4B | 22,000 | 674 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 754 |
| Cardinal Health | $48,123 | $226.8B | 48,000 | 6,626 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,710 |
| Merck | $90,328 | $64.2B | 74,000 | 1,780 |
| BD | $69,049 | $19.4B | 76,032 | 256 |
| Biogen | $92,036 | $9.7B | 9,100 | 111 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Baxter International highest paying jobs
Zippia gives an in-depth look into the details of Baxter International, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Baxter International. The employee data is based on information from people who have self-reported their past or current employments at Baxter International. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Baxter International. The data presented on this page does not represent the view of Baxter International and its employees or that of Zippia.
Baxter International may also be known as or be related to Baxter International, Baxter International Inc, Baxter International Inc., Baxter International, Inc. and baxter.